Ulixertinib by BioMed Valley Discoveries for Neurofibromatoses Type I (Von Recklinghausen’s Disease): Likelihood of Approval

Ulixertinib is under clinical development by BioMed Valley Discoveries and currently in Phase I for Neurofibromatoses Type I (Von Recklinghausen’s Disease).

Three quarters of trusts in England still use paper patient notes and drug charts

Three quarters of trusts in England that responded to a survey by The BMJ are still reliant on paper patient notes and drug charts, despite

September 14, 2023

Roche’s Tecentriq SC receives EC approval for cancer treatment

Share this article The marketing authorisation is applicable for all existing indications approved in the EU for Roche’s Tecentriq IV. Credit: F. Hoffmann-La Roche. Roche

January 16, 2024

Radiotherapy may cause low-grade intestinal inflammation in cancer survivors

Patients who have undergone pelvic radiotherapy may live with low-grade chronic inflammation of the lower intestine 20 years after the treatment. 0

September 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.